Press Releases Keyword Search Year None20202019201820172016201520142013 11/23/20 Avadel Pharmaceuticals to Present at Upcoming December 2020 Investor Conferences DUBLIN, Ireland , Nov. 23, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 11/11/20 Avadel Pharmaceuticals to Present at Upcoming November 2020 Investor Conferences DUBLIN, Ireland , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 11/09/20 Avadel Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Update on FT218 Development Program NDA for once-nightly FT218 is on track for FDA submission by end of December 2020 New market asses... 10/26/20 Avadel Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 9th DUBLIN, Ireland , Oct. 26, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 09/17/20 Avadel to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit DUBLIN, Ireland , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a com... 09/14/20 Avadel Pharmaceuticals Announces FT218 Leadership Transition Jordan Dubow , M.D. stepping down as CMO and will continue as a consultant to the Company through th... 09/11/20 Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference DUBLIN, Ireland , Sept. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a com... 08/10/20 Avadel Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent Business Update Presented positive topline data from the pivotal Phase 3 REST-ON study Announced today that results ... 07/27/20 Avadel Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10th DUBLIN, Ireland , July 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) announ... 07/13/20 Avadel Pharmaceuticals Announces First Patient Dosed in Open-Label Extension/Switch Study of Investigational Once-Nightly FT218 as a Potential Treatment for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy Clinical study to enroll 250 patients from sites that participated in the REST-ON study Study to exa... 07/01/20 Avadel Announces Sale of Hospital Sterile Injectable Drug Portfolio for $42.0 Million DUBLIN, Ireland , July 01, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 06/08/20 Avadel Pharmaceuticals to Present at BIO Digital DUBLIN, Ireland , June 08, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a comp... 06/01/20 Avadel Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference DUBLIN, Ireland , June 01, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a comp... 05/11/20 Avadel Pharmaceuticals Reports First Quarter 2020 Financial Results Reported positive topline data from the pivotal Phase 3 REST-ON study Strengthened balance sheet wit... 05/04/20 Avadel Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11th DUBLIN, Ireland , May 04, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a comp... 04/28/20 Avadel Pharmaceuticals Announces Pricing of Public Offering DUBLIN, Ireland , April 28, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 04/27/20 Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering DUBLIN, Ireland , April 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 04/27/20 Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy The primary analysis of investigational, once-nightly FT218 at 9 g demonstrated highly statistically... 03/25/20 Avadel Pharmaceuticals Completes the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy Topline data from the REST-ON study expected in Q2 2020 DUBLIN, Ireland , March 25, 2020 (GLOBE NEWS... 03/12/20 Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Completed enrollment for the pivotal REST-ON Phase 3 study in Q4 2019; data readout expected in Q2 2... 02/27/20 Avadel Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results on March 12th DUBLIN, Ireland , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 02/21/20 Avadel Pharmaceuticals Announces $65 Million Private Placement with Leading Biotech Investment Funds DUBLIN, Ireland , Feb. 21, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
11/23/20 Avadel Pharmaceuticals to Present at Upcoming December 2020 Investor Conferences DUBLIN, Ireland , Nov. 23, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
11/11/20 Avadel Pharmaceuticals to Present at Upcoming November 2020 Investor Conferences DUBLIN, Ireland , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
11/09/20 Avadel Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Update on FT218 Development Program NDA for once-nightly FT218 is on track for FDA submission by end of December 2020 New market asses...
10/26/20 Avadel Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 9th DUBLIN, Ireland , Oct. 26, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
09/17/20 Avadel to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit DUBLIN, Ireland , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a com...
09/14/20 Avadel Pharmaceuticals Announces FT218 Leadership Transition Jordan Dubow , M.D. stepping down as CMO and will continue as a consultant to the Company through th...
09/11/20 Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference DUBLIN, Ireland , Sept. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a com...
08/10/20 Avadel Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent Business Update Presented positive topline data from the pivotal Phase 3 REST-ON study Announced today that results ...
07/27/20 Avadel Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10th DUBLIN, Ireland , July 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) announ...
07/13/20 Avadel Pharmaceuticals Announces First Patient Dosed in Open-Label Extension/Switch Study of Investigational Once-Nightly FT218 as a Potential Treatment for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy Clinical study to enroll 250 patients from sites that participated in the REST-ON study Study to exa...
07/01/20 Avadel Announces Sale of Hospital Sterile Injectable Drug Portfolio for $42.0 Million DUBLIN, Ireland , July 01, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
06/08/20 Avadel Pharmaceuticals to Present at BIO Digital DUBLIN, Ireland , June 08, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a comp...
06/01/20 Avadel Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference DUBLIN, Ireland , June 01, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a comp...
05/11/20 Avadel Pharmaceuticals Reports First Quarter 2020 Financial Results Reported positive topline data from the pivotal Phase 3 REST-ON study Strengthened balance sheet wit...
05/04/20 Avadel Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11th DUBLIN, Ireland , May 04, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a comp...
04/28/20 Avadel Pharmaceuticals Announces Pricing of Public Offering DUBLIN, Ireland , April 28, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
04/27/20 Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering DUBLIN, Ireland , April 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
04/27/20 Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy The primary analysis of investigational, once-nightly FT218 at 9 g demonstrated highly statistically...
03/25/20 Avadel Pharmaceuticals Completes the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy Topline data from the REST-ON study expected in Q2 2020 DUBLIN, Ireland , March 25, 2020 (GLOBE NEWS...
03/12/20 Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Completed enrollment for the pivotal REST-ON Phase 3 study in Q4 2019; data readout expected in Q2 2...
02/27/20 Avadel Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results on March 12th DUBLIN, Ireland , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
02/21/20 Avadel Pharmaceuticals Announces $65 Million Private Placement with Leading Biotech Investment Funds DUBLIN, Ireland , Feb. 21, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
